Sopharma AD sells small portion of treasury shares on Bulgarian Stock Exchange

Ognian Ivanov Donev
Ognian Ivanov Donev
0Comments

Sopharma AD has announced the sale of 1,100 treasury shares on August 18, 2025. The transaction took place on the Bulgarian Stock Exchange with a total value of BGN 2,707.00 and an average price per share of BGN 2.46.

Following this sale, the company now holds a total of 21,037,732 treasury shares. This amount represents 3.90% of Sopharma AD’s share capital.

“Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 18, 2025 the Company sold 1 100 (one thousand one hundred) treasury shares representing 0.0002% of the share capital of the Company, at a total value of BGN 2 707.00 on the Bulgarian Stock Exchange, the average price per share was BGN 2.46.”

The company made this disclosure in accordance with Article 17 of Regulation (EU) No 596/2014 from the European Parliament and Council.

The sale has a minor impact on Sopharma AD’s overall share capital percentage.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.